Abbvie (ABBV) PT Lowered to $84 at Morgan Stanley
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $265.97 +2.72%
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Morgan Stanley analyst David Risinger lowered the price target on Abbvie (NYSE: ABBV) to $84.00 (from $88.00) while maintaining a Equalweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) PT Raised to $89 at Morgan Stanley
- Wolfe Research Upgrades Abbvie (ABBV) to Outperform
- Morgan Stanley Upgrades HDB Financial Services (HDBFS:IN) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
